Coenzyme M
- Generic Name
- Coenzyme M
- Brand Names
- Uromitexan
- Drug Type
- Small Molecule
- Chemical Formula
- C2H6O3S2
- CAS Number
- 3375-50-6
- Unique Ingredient Identifier
- VHD28S0H7F
- Background
Coenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Indication
Mesna is a uroprotective agent and is used prophylactically to reduce ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Associated Conditions
- Hemorrhagic cystitis caused by cyclophosphamide, Hemorrhagic cystitis caused by ifosfamide
Cardiac Safe Transplants for Systemic Sclerosis
- Conditions
- Systemic SclerosisScleroderma
- Interventions
- Biological: IVIgBiological: Autologous Stem Cells
- First Posted Date
- 2018-07-20
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 9
- Registration Number
- NCT03593902
- Locations
- 🇺🇸
Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Liver Transplantation With Tregs at MGH
- Conditions
- Liver Transplant
- Interventions
- First Posted Date
- 2018-07-05
- Last Posted Date
- 2025-01-13
- Target Recruit Count
- 9
- Registration Number
- NCT03577431
- Locations
- 🇺🇸
Massachusetts General Hospital: Transplantation, Boston, Massachusetts, United States
Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic Leukemia, Refractory
- Interventions
- Device: CliniMACSBiological: CD19- specific CAR engineered autologous T-cells (SJCAR19 product)
- First Posted Date
- 2018-06-29
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT03573700
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Maximizing Outcome of Multiple Sclerosis Transplantation
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Biological: Autologous Stem CellsBiological: IVIg
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 66
- Registration Number
- NCT03342638
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma
- Conditions
- Soft Tissue Sarcoma
- Interventions
- First Posted Date
- 2017-09-14
- Last Posted Date
- 2020-09-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT03283696
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Miami School of Medicine, Miami, Florida, United States
🇩🇪Universitätsklinikum Essen, Essen, Nordrhein-Westfalen, Germany
Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)
- Conditions
- Sickle Cell Disease
- Interventions
- Procedure: Haploidentical Bone Marrow TransplantationDrug: Rabbit-ATGRadiation: Total Body Irradiation
- First Posted Date
- 2017-08-28
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 95
- Registration Number
- NCT03263559
- Locations
- 🇺🇸
Texas Children's Hospital (Baylor), Houston, Texas, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Nicklaus Children's Hospital/University of Miami Children's Hospital, Miami, Florida, United States
Evaluating Different Modalities for Pleural Adhesiolysis at Assuit University Hospital
- Conditions
- Pleural Effusion
- Interventions
- Device: Medical thoracoscopyDevice: Video assisted thoracoscopy (VATS)
- First Posted Date
- 2017-06-01
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 100
- Registration Number
- NCT03172052
Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies
- Conditions
- Acute Lymphocytic LeukemiaChronic Lymphocytic LeukemiaNon-hodgkin LymphomaB-Lymphoid Malignancies
- Interventions
- Biological: iC9/CAR.19/IL15-Transduced CB-NK Cells
- First Posted Date
- 2017-02-17
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 49
- Registration Number
- NCT03056339
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Umbilical Cord Blood Transplantation From Unrelated Donors
- Conditions
- Metabolism DisorderLymphomaAplastic AnemiaAcute LeukemiaMyelodysplastic SyndromesCongenital Hematological DisorderChronic LeukemiaMultiple MyelomaImmune Deficiency DisorderSolid Tumor
- Interventions
- Procedure: Cord Blood InfusionRadiation: Total Body Irradiation 200 cGyRadiation: Total Body Irradiation 1200 cGy
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 30
- Registration Number
- NCT03016806
- Locations
- 🇺🇸
Wilmot Cancer Institute, Rochester, New York, United States
Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor
- Conditions
- Hematologic Malignancy
- Interventions
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT02880293
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.